Skip to main content
SpringerLink
Log in

Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiationin vitro

  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

This article revies the patterns of cross-resistance identified in various P-glycoprotein-mediated and non-P-glycoprotein-mediated drug resistant mammalian tumour cell lines. The differing patterns of cross-resistance and the variable levels of resistance expressed are summarised and discussed. Although the mechanism by which P-glycoprotein can recognise and transport a large group of structurally-unrelated substrates remains to be defined, the recent evidence indicating that membrane associated domains participate in substrate recognition and binding is summarised, and other possible explanations for these variable cross-resistance patterns are considered. Amongst the non-P-glycoprotein-overexpressing multidrug resistant cell lines, two subsets are clearly identifiable, one lacking and the other expressing cross-resistance to the Vinca alkaloids. Resistance mechanisms implicated in these various sublines and possible explanations for their differing levels and patterns of cross-resistance are summarised.

Clinical resistance is identified in patients following treatment not only with antitumour drugs, but also after radiotherapy. Experimental data providing a biological basis for this observation are summarised. A distinctive multiple drug resistance phenotype has been identified in tumour cells following exposurein vitro to fractionated X-irradiation characterised by: the expression of resistance to the Vinca alkaloids and the epipodophyllotoxins but not the anthracyclines and overexpression of P-glycoprotein which is post-translationally regulated, but without any concomitant overexpression of P-glycoprotein mRNA.

Finally, the possible clinical relevance of these variable patterns of cross-resistance to the antitumour drugs commonly used in the clinic is considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abbaszadegan MR, Futscher BW and Dalton WS (1993) Evaluation of verapamil resistance in a multi-drug resistant myeloma cell line. Proc Am Assoc Cancer Res 34:324.

    Google Scholar 

  • Akiyama SI, Fojo A, Hanover JA, Pastan I and Gottesman MM (1985) Isolation and genetic characterisation of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genetic 11:117–126.

    Google Scholar 

  • Baas F, Jongsma A, Broxterman H, Arceci R, Housman D, Scheffer G, Riethorst A, Van Groeningen M, Nieuwint A and Joense H (1990) Non P-glycoprotein mediated mechanism for MDR precedes P-glycoprotein expression duringin vitro selection for doxorubicin resistance in human cancer cell line. Cancer Res 50:5392–5398.

    Google Scholar 

  • Barrand MA, Rhodes T, Center MS and Twentyman PR (1993) Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer 29A: 408–415.

    Google Scholar 

  • Bates SE, Currier SJ, Alvarez M and Fojo AT (1992) Modulation of P-glycoprotein phosphorylation and drug transport by sodium butyrate. Biochem 31: 6366–6372.

    Google Scholar 

  • Bech-Hansen NTG, Till TE and Ling V (1976) Pleitropic phenotype of colchicine resistant CHO cells: Cross-resistance and collateral sensitivity. J Cell Physiol 88: 23–32.

    Google Scholar 

  • Beck WT (1984) Cellular pharmacology of Vinca alkaloid resistance and its circumvention. Adv Enzyme Regul 22: 207–227.

    Google Scholar 

  • Beck WT (1989) Unknotting the complexities of multidrug resistance: The involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst 81: 1683–1685.

    Google Scholar 

  • Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP and Trent JM (1987) Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug-resistant human leukemic cells. Cancer Res 47: 5455–5460.

    Google Scholar 

  • Beck WT and Danks MK (1991) Characteristics of multidrug resistance in human tumor cells. In: IB Roninson (ed) Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells (pp 3–55). Plenum Press, New York.

    Google Scholar 

  • Beck WT, Muller TJ and Tanzer LR (1979) Altered surface membrane glycoproteins in Vinca alkaloïd resistant human leukemic lymphoblasts. Cancer Res 39: 2070–2076.

    Google Scholar 

  • Bedford P, Shellard SA, Walker C, Whelan RDH, Masters JRW and Hill BT (1987) Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposedin vitro to either X-irradiation or cisplatin. Int J Cancer 40: 681–686.

    Google Scholar 

  • Bellamy AS and Hill BT (1984) Murine L5178Y cells resulting in altered drug sensitivities from fractionated radiation exposurein vitro. J Natl Cancer Inst 72: 411–417.

    Google Scholar 

  • Benard J, Da Silva J, Teyssier J-R and Riou G (1989) Overexpression ofMDR1 gene with no DNA amplification in a multiple drug resistant human ovarian carcinoma cell line. Int J Cancer 43: 471–477.

    Google Scholar 

  • Biedler JL, Casals D, Chang T-D, Meyers MB, Spengler BA and Ross RA (1991) Multidrug-resistant human neuroblastoma cells are more differentiated than controls and retinoic acid further induces lineage-specific differentiation. In: AE Evans, GJ D'Anglio, AG Knudson Jr, RC Seeger (eds) Advances in Neuroblastoma Research 3 (pp 181–191). Wiley-Liss, New York.

    Google Scholar 

  • Biedler JL, Meyers MB and Spengler BA (1988) Cellular concomitants of multidrug resistance. In: PV Woolley III, KD Tew (eds) Mechanisms of Drug Resistance in Neoplastic Cells (pp 41–68). Academic Press, New York.

    Google Scholar 

  • Biedler JL and Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cellsin vitro: Cross-resistance, radioautographic and cytogenetic studies. Cancer Res 30: 1174–1184.

    Google Scholar 

  • Bradley G, Naik M and Ling V (1989) P-glycoprotein expression in multidrug resistant human ovarian carcinoma cell lines. Cancer Res 49: 2790–2796.

    Google Scholar 

  • Chabner BA (1986) The oncologic end game. J Clin Oncol 4: 625–638.

    Google Scholar 

  • Chan HSL, Thorner PS, Haddad G and Ling V (1990) Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 8: 689–704.

    Google Scholar 

  • Chaudhary PM and Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632–639.

    Google Scholar 

  • Chen Y-N, Mickley LA, Schwartz AM, Acton EM, Hwang J and Fojo AT (1990) Characterization of Adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 265: 10073–10080.

    Google Scholar 

  • Choi K, Chen C-J, Kriegler M and Roninson IB (1988) An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in themdr1 (P-glycoprotein) gene. Cell 53: 519–529.

    Google Scholar 

  • Clynes M, Redmond A, Moran E and Gilvarry U (1992) Multiple drug-resistance in variant of a human nonsmall cell lung carcinoma cell line, DLKP-A. Cytotechnol 10: 75–89.

    Google Scholar 

  • Cohen D, Yang C-HP and Horwitz SB (1990) The products of the mdr 1a and mdr1b genes from multidrug resistant murine cells have similar degradation rates. Life Sci 46: 489–495.

    Google Scholar 

  • Cole SPC (1992) The MERCK Frosst Award. Multidrug resistance in small cell lung cancer. Cancer J Physiol Pharmacol 70: 313–329.

    Google Scholar 

  • Cole SPC, Bhardwaj G, Gerlach JH, MacKie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650–1654.

    Google Scholar 

  • Cole SPC, Chanda ER, Dicke FP, Gerlach JH and Mirski SEL (1991) Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 51: 3345–3352.

    Google Scholar 

  • Coley HM, Twentyman PR and Workman P (1989) Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines and further resistance modification by verapamil and cyclosporin A. Biochem Pharmacol 38: 4467–4475.

    Google Scholar 

  • Coley HM, Workman P and Twentyman PR (1991) Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer 63: 351–357.

    Google Scholar 

  • Conter V and Beck WT (1984) Acquisition of multiple drug resistance by CCRF-CEM cells selected fro different degrees of resistance to vincristine. Cancer Treat Rep 68: 831–839.

    Google Scholar 

  • Dalton WS (1990) Reversing multidrug resistance in the laboratory and the clinic. Proc Am Assoc Cancer Res 31: 520–521.

    Google Scholar 

  • Dalton WS, Durie BGM, Alberts DS, Gerlach JH and Cress AE (1986) Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 46: 5125.

    Google Scholar 

  • Dalton WS, Gleason-Guzman MC and Foley NE (1993) Mitoxantrone selects for non-P-glycoprotein resistance in a human myeloma cell line. Proc Am Assoc Cancer Res 34: 305.

    Google Scholar 

  • Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM and Salmon SE (1989) Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73: 747–752.

    Google Scholar 

  • Danks MK, Schmidt CA, Cirtain MC, Suttle DP and Beck WT (1988) Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861–8869.

    Google Scholar 

  • Danks MK, Schmidt CA, Deneka DA and Beck WT (1989) Increased ATP requirement for activity of a complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide. Cancer Commun 1: 101–109.

    Google Scholar 

  • Danks MK, Yalowich JC and Beck WT (1987) Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide. Cancer Res 47: 1297–1301.

    Google Scholar 

  • Dano K (1972) Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumourin vivo. Cancer Chemother Res 56: 701–708.

    Google Scholar 

  • De Bruijn MHL, Van der Bliek AM, Biedler JL and Borst P (1986) Differential amplification and disproportionate expression of five genes in three multidrug-resistant Chinese hamster lung cell lines. Mol Cell Biol 6: 4717–4722.

    Google Scholar 

  • Deffie AM, Alam T, Seneviratne C, Beenken SW, Batra JK, Shea TC, Henner WD and Goldenberg GJ (1988) Multifactorial resistance to Adriamycin: Relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of Adriamycin-sensitive and-resistant P388 leukemia. Cancer Res 48: 3595–3602.

    Google Scholar 

  • Deffie AM, McPherson JP, Gupta RS, Hedley DW and Goldenberg GJ (1992) Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary and human HeLa cells, with emphasis on the role of DNA topoisomerase II. Biochem Cell Biol 70: 354–364.

    Google Scholar 

  • De Jong S, Kooistra AJ, De Vries EGE, Mulder NH and Zijlstra JG (1993) Topoisomerase II as a target of VM-26 and 4′-(9-acridinylamino) methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res 53: 1064–1071.

    Google Scholar 

  • De Jong S, Zijstra JG, De Vries EGE and Mulder NH (1990) Reduced DNA topoisomerase II activity and drug-induced cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50: 304–309.

    Google Scholar 

  • Dempke WCM, Whelan RDH and Hill BT (1992) Expression of resistance to etoposide and vincristinein vitro andin vivo after X-irradiation of ovarian tumour cells. Anti-Cancer Drugs 3: 395–399.

    Google Scholar 

  • Devine SE, Ling V and Melera PW (1992) Amino acid substitutions in the sixth transmembrane domain of P-glycoprotein alter multidrug resistance. Proc Natl Acad Sci USA 89: 4564–4568.

    Google Scholar 

  • DeVita Jr VT (1989) The problem of resistance: Keynote address. In: E Mihich (ed) Pezcoller Foundation Symposia Trento — Italy 1: Drug Resistance — Mechanisms and Reversal (pp 7–27) John Libbey, Rome.

    Google Scholar 

  • Dhir R and Gros P (1992) Functional analysis of chimeric proteins constructed by exchanging homologous domains of two P-glycoproteins conferring distinct drug resistance profiles. Biochem 31: 6103–6110.

    Google Scholar 

  • Dietel M, Arps H, Lage J and Niendorf A (1990) Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG 85-257. Cancer Res 50: 6100–6106.

    Google Scholar 

  • Domenech C, Spengler BA, Ross RA and Biedler JL (1993) Prolonged half-life in a multidrug-resistant N-myc-amplified human neuroblastoma cell line. Proc Am Assoc Cancer Res 34: 16.

    Google Scholar 

  • Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST and Mirabelli CK (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28: 8154–8160.

    Google Scholar 

  • Drake FH, Zimmerman JP, McCabe FL, Bartus HF, Per SR, Sullivan DM, Ross WE, Mattern MR, Johnson RK, Crooke ST and Mirabelli CK (1987) Purification of topoisomerase II from Amsacrine-resistant P388 leukemia cells. J Biol Chem 262: 16739–16747.

    Google Scholar 

  • Eijdems EWHM, Borst P, Jongsma APM, de Jong S, De Vries EGE, Van Groeningen M, Versantvoort CHM, Nieuwint AWM and Baas F (1992) Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: Dissection of a compound MDR phenotype. Proc Natl Acad Sci USA 89: 3498–3502.

    Google Scholar 

  • Fairchild CR, Ivy SP, Kao-Shan C-S, Whang-Peng J, Rosen N, Israel MA, Melera PW, Cowan KH and Goldsmith ME (1987) Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res 47: 5141–5148.

    Google Scholar 

  • Farber S, Diamond LK, Mercer RD, Sylvester RF and Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). New Engl J Med 238: 787–793.

    Google Scholar 

  • Ferguson PJ, Fisher MH, Stephenson J, Li D-H, Zhou B-S and Cheng Y-C (1988) Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 48: 5956–5964.

    Google Scholar 

  • Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM and Pastan I (1987) Expression of a multidrug-resistance gene in human tumours and tissues. Proc Natl Acad Sci USA 84: 265–269.

    Google Scholar 

  • Fojo AT, Whang-Peng J, Gottesman MM and Pastan I (1985) Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 82: 7661–7665.

    Google Scholar 

  • Gervasoni JE, Taub RN, Yu MT, Warburton D, Sabbath M, Gilleran S, Koppock DL, D'Alessanderi J, Kirshna S, Rosado M, Baker MA, Lutsky J, Chanda ER, Gerlach JH, Pinoski M, Cole SPC and Hindenburg AA (1992) Homogeneously staining region in anthracycline-resistant HL60/AR cells not associated with MDR1 amplification. Cancer Res 52: 5244–5249.

    Google Scholar 

  • Goldie JH and Coldman AJ (1979) A mathematical model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733.

    Google Scholar 

  • Goldie JH and Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44: 3643–3653.

    Google Scholar 

  • Greenberger LM, Lothstein L, Williams SS and Horwitz SB (1988) Distinct P-glycoprotein precursers are overproduced in independently isolated drug-resistant cell lines. Proc Natl Acad Sci USA 85: 3762–3766.

    Google Scholar 

  • Greenberger LM, Williams SS and Horwitz SB (1987) Biosynthesis of heterogeneous forms of multidrug resistance-associated glycoproteins. J Biol Chem 262: 13685–13789.

    Google Scholar 

  • Greenspan EM, Feiber M, Lesnick G and Edelman S (1963) Response of advanced breast cancer to the combination of the antimetabolite methotrexate and the alkylating agent thiotepa. J Mount Sinai Hosp 30: 246–267.

    Google Scholar 

  • Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter M, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T and Salmon S (1990) Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest 63: 815–824.

    Google Scholar 

  • Gros P, Dhir R, Croop J and Talbot F (1991) A single amino acid substitution strongly modulates the activity and substrate specificity of the mouse mdr1 and mdr3 drug efflux pumps. Proc Natl Acad Sci USA 88: 7289–7293.

    Google Scholar 

  • Gudkov AW, Zelnick C, Kazarov AR, Thimmapaya R, Suttle DP, Beck WT and Roninson IB (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci USA 90: 3231–3235.

    Google Scholar 

  • Hait WN, Choudhury S, Srimatkandada S and Murren JR (1993) Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. J Clin Invest 91: 2207–2215.

    Google Scholar 

  • Hamada H, Akochi E, Watanabe M, Oh-Hara T, Sugimoto Y, Kawabata H and Tsuruo T (1988)M r85,000 membrane protein specifically expressed in Adriamycin-resistant human tumor cells. Cancer Res 48: 7082–7087.

    Google Scholar 

  • Harker WG and Sikic BI (1985) Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. Cancer Res 45: 4091–4096.

    Google Scholar 

  • Harker WG, Slade DL, Drake FH and Parr RL (1991) Mitoxantrone resistance in HL-60 leukemia cells: Reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II β isoform. Biochemistry 30: 9953–9961.

    Google Scholar 

  • Hill BT (1986)In vitro human tumour model systems for investigating drug resistance. Cancer Surveys 5: 129–149.

    Google Scholar 

  • Hill BT (1990)In vitro drug-radiation interactions using fractionated X-irradiation regimens. In: BT Hill, AS Bellamy (eds) Antitumor Drug-Radiation Interactions (pp 207–222). CRC Press Inc., Boca Raton, Florida.

    Google Scholar 

  • Hill BT (1991) Interactions between antitumour agents and radiation and the expression of resistance. Cancer Treat Rev 18: 149–190.

    Google Scholar 

  • Hill BT and Bellamy AS (1984) Establishment of an etoposide-resistant human epithelial tumour cell linein vitro: Characterisation of patterns of cross-resistance and drug sensitivities. Int J Cancer 33: 599–608.

    Google Scholar 

  • Hill BT, Deuchars K, Hosking LK, Ling V and Whelan RDH (1990) Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X-irradiationin vitro. J Natl Cancer Inst 82: 607–612.

    Google Scholar 

  • Hill BT, Hosking LK, Shellard SA and Whelan RDH (1989) Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell linesin vitro. Cancer Chemother Pharmacol 23: 140–144.

    Google Scholar 

  • Hill BT and Whelan RDH (1982) Establishment of vincristine-resistant and vindesine-resistant lines of murine lymphobiastsin vitro and characterisation of their patterns of cross-resistance and drug sensitivities. Cancer Chemother Pharmacol 8: 163–169.

    Google Scholar 

  • Hill BT, Whelan RDH, Hosking LK, Hinds MD, Mayes J and Zwelling LA (1991) A lack of detectable modification of topoisomerase II activity in a series of human tumour cell lines expressing only low levels of etoposide resistance. Int J Cancer 47: 899–902.

    Google Scholar 

  • Hill BT, Whelan RDH, Hosking LK, Shellard SA, Bedford P and Lock RB (1988) Interactions between antitumor drugs and radiation in mammalian tumor cell lines: Differential drug responses and mechanisms of resistance following fractionated X-irradiation or continuous drug exposurein vitro. Natl Cancer Inst Monogr 6: 177–181.

    Google Scholar 

  • Hill BT, Whelan RDH and McClean S (1993) Overexpression and posttranslational regulation of P-glycoprotein resulting from exposure of human ovarian tumour cells to fractionated X-irradiation. Proc Am Soc Clin Oncol 12: 118.

    Google Scholar 

  • Hochhauser D and Harris AL (1993) The role of topoisomerase II α and β in drug resistance. Cancer Treat Rev 19: 181–194.

    Google Scholar 

  • Horwitz SB, Liao L-L, Greenberger L and Lothstein L (1989) Mode of action of taxol and characterization of a multidrug-resistant cell line selected with taxol. In: D Kessel (ed) Resistance to Antineoplastic Drugs (pp 109–125). CRC Press, Boca Raton, Florida.

    Google Scholar 

  • Hosking L, Shellard S, McClean S and Hill B (1993) Modified topoisomerase II expression appears to predominate in drug-and X-ray-selected etoposide resistant human testicular teratoma sublines. Br J Cancer 67 (Suppl. XX): 76.

    Google Scholar 

  • Hsu SI-H, Lothstein L and Horwitz SB (1989) Differential overexpression of threemdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem 264: 12053–12062.

    Google Scholar 

  • Ikeguchi M, Teeter LD, Eckersberg T, Ganapathi R and Kun MT (1991) Structural and functional analyses of the promoter of the murine multidrug resistance gene mdr3/mdr 1a reveal a negative element containing the AP-1 binding site. DNA and Cell Biol 10: 639–647.

    Google Scholar 

  • Juliano RL and Ling V (1976) Surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152–162.

    Google Scholar 

  • Kartner N, Everden-Porelle D, Bradley G and Ling V (1985) Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 316: 820–823.

    Google Scholar 

  • Kartner N, Riordan JR and Ling V (1983) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cells. Science 221: 1285–1288.

    Google Scholar 

  • Kastan MB, Onyekwere O, Sidaransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304–6311.

    Google Scholar 

  • Keizer HG, Schuurhuis GJ, Broxterman HJ, Lankelma J, Schoonen WGEJ, Van Rijn J, Pinedo HM and Joenje H (1989) Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res 49: 2988–2993.

    Google Scholar 

  • Kellner V, Boege F, Gieseler F and Dietel M (1993) Alterated DNA topoisomease II in mitoxantrone resistant human Gastric carcinoma celline. Proc Am Assoc Cancer Res 34: 330.

    Google Scholar 

  • Kessel D (1986) Circumvention of resistance to anthracyclines by calcium antagonists and other membrane-perturbing agents. Cancer Surveys 5: 109–127.

    Google Scholar 

  • Kirschner LS, Greenberger LM, Hsu SI-H, Yang C-PH, Cohen D, Piekarz RL, Castillo G, Han EK-H, Yu L and Horwitz SB (1992) Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells. Biochem Pharmacol 43: 77–87.

    Google Scholar 

  • Kohno K, Kikuchi J, Sato S-I, Takano H, Saburi Y, Asoh K-I and Kuwano M (1988) Vincristine-resistant human cancer KB cell line and increased expression of multidrug-resistance gene. Jpn J Cancer Res 79: 1238–1246.

    Google Scholar 

  • Kohno K, Sato S-I, Uchiumi T, Takano H, Tanimura H, Miyazaki M, Matsuo K-I, Hidaka K and Kuwano M (1992) Activation of the human multidrug resistance 1 (MDR1) gene promoter in response to inhibitors of DNA topoisomerases. Int J Oncol 1: 73–77.

    Google Scholar 

  • Kramer RA, Zakher J and Kim G (1988) Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science 241: 694–697.

    Google Scholar 

  • Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer DL, Lankelma J and Pinedo HM (1990) Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1: 35–41.

    Google Scholar 

  • Levine AJ (1992) The p53 tumour supressor gene and product. In: AJ Levine (ed) Cancer Surveys 12: Tumour Supressor Genes, the Cell Cycle and Cancer (pp 59–78). Cold Spring Harbour Press, New York.

    Google Scholar 

  • Lincke CR, Van der Bliek AM, Schuurhuis GJ, Van der Velde-Koerts T, Smit JJM and Borst P (1990) Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type humanmdr1 complementary DNA. Cancer Res 50: 1779–1785.

    Google Scholar 

  • Ling V, Kartner N, Sudo T, Siminovitch L and Riordan JR (1983) Multidrug-resistance phenotype in Chinese hamster ovary cells. Cancer Treat Rep 67: 869–874.

    Google Scholar 

  • Ling V and Thompson LH (1974) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83: 103–116.

    Google Scholar 

  • Lock RB and Hill BT (1988) Differential patterns of antitumour drug responses and mechanisms of resistance in a series of independently-derived VP-16-resistant human tumour cell lines. Int J Cancer 42: 373–381.

    Google Scholar 

  • Maltzman W and Czyzyk L (1984) UV irradiation stimulates levels of p53 tumor antigen in nontransformed mouse cells. Mol Cell Biol 4: 1689–1694.

    Google Scholar 

  • Marquardt D and Center MS (1992) Drug transport mechanisms in the HL60 cells isolated for resistance to Adriamycin: Evidence for nuclear drug accumulation and redistribution in resistant cells. Cancer Res 52: 3157–3163.

    Google Scholar 

  • Marquardt D, McCrone S and Center MS (1990) Mechanisms of multidrug resistance in HL-60 cells: Detection of resistance associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 50: 1426–1430.

    Google Scholar 

  • Mattern J, Efferth T and Volm M (1991) Overexpression of P-glycoprotein in human lung carcinoma xenografts after fractionated irradiationin vivo. Radiat Res 127: 335–338.

    Google Scholar 

  • McClean S, Dempke WCM, Whelan RDH, Hosking LK and Hill BT (1992) Overexpression of P-glycoprotein in human ovarian carcinoma cells following exposure to fractionated X-irradiationin vitro. Proc Am Assoc Cancer Res 33: 470.

    Google Scholar 

  • McClean S and Hill BT (1992) An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugsin vitro. Biochim Biophys Acta 1114: 107–127.

    Google Scholar 

  • McClean S and Hill BT (1993) Posttranslational regulation of P-glycoprotein in mammalian tumour cells expressing a distinctive multiple drug resistance phenotype after exposure to fractionated X-irradiation. Proc Am Assoc Cancer Res 34: 313.

    Google Scholar 

  • McClean S, Hosking LK and Hill BT (1993a) Dominant expression of multiple drug resistance afterin vitro X-irradiation exposure in intraspecific Chinese hamster ovary hybrid cells. J Natl Cancer Inst 85: 48–53.

    Google Scholar 

  • McClean S, Hosking LK and Hill BT (1993b) Expression of P-glycoprotein-mediated drug resistance in Chinese hamster ovary cells survivingin vitro exposure to a single lethal X-ray dose of 30Gy. Int J Radiat Biol 63: 765–773.

    Google Scholar 

  • McClean S, Whelan RDH, Hosking LK, Hodges GM, Thompson FH, Meyers MB, Schuurhuis GJ and Hill BT (1993c) Characterisation of the P-glycoprotein overexpressing drug resistance phenotype exhibited by Chinese hamster ovary cells following theirin vitro exposure to fractionated X-irradiation. Biochim Biophys Acta 1177: 117–126.

    Google Scholar 

  • McGrath T and Center MS (1987) Adriamycin resistance in HL-60 cells in the absence of detectable P-glycoprotein. Biochem Biophys Res Commun 145: 1171–1176.

    Google Scholar 

  • McGrath T and Center MS (1988) Mechanisms of multidrug resistance in HL60 cells: Evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 48: 3959–3963.

    Google Scholar 

  • Meyers MB, Spengler BA, Chang T-D, Melera PW and Biedler JL (1985) Gene amplification-associated cytogenetic aberrations and protein changes in vincristine-resistant Chinese hamster, mouse, and human cells. J Cell Biol 100: 588–597.

    Google Scholar 

  • Mirski SEL, Evans CD, Almquist KC, Slovak ML and Cole SPC (1993) An altered topoisomerase II α in a drug resistant small cell lung cancer cell line selected in VP-16. Cancer Res (in press).

  • Mirski SEL, Gerlach JH and Cole SPC (1987) Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res 47: 2594–2598.

    Google Scholar 

  • Muller C and Ling V (1992) P-glycoprotein is affected by serum deprivation and high cell density in multidrug resistant cells. Proc Am Assoc Cancer Res 33: 452.

    Google Scholar 

  • Nielsen D and Skovsgaard T (1992) P-glycoprotein as a multidrug transporter: A critical review of current multidrug resistant cell lines. Biochim Biophys Acta 1139: 169–183.

    Google Scholar 

  • Nieuwint AWM, Baas F, Wiegant J and Joenje H (1992) Cytogenic alterations associated with P-glycoprotein- and non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung tumor cell lines. Cancer Res 52: 4361–4371.

    Google Scholar 

  • Patel S and Fisher LM (1993) Novel selection and genetic characterisation of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br J Cancer 67: 456–463.

    Google Scholar 

  • Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP and Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83: 105–110.

    Google Scholar 

  • Peterson RHF, Meyers MB, Spengler BA and Biedler JL (1983) Alteration of plasma membrane glycopeptides and gangliosides of Chinese hamster cells accompanying development of resistance to daunorubicin and vincristine. Cancer Res 43: 222–228.

    Google Scholar 

  • Reeve JG, Rabbits PH and Twentyman PR (1990) Non-P-glycoprotein mediated multidrug resistance with reduced EGFR expression in a human large cell lung cancer cell line. Br J Cancer 61: 851–855.

    Google Scholar 

  • Riehm H and Biedler JL (1971) Cellular resistance to daunomycin in Chinese hamster cellsin vitro. Cancer Res 31: 409–412.

    Google Scholar 

  • Riordan JR, Deuchars K, Kartner N, Alon N, Trent J and Ling V (1985) Amplification of P-glycoprotein genes in multi-drug resistant mammalian cell lines. Nature 316: 817–819.

    Google Scholar 

  • Rogan AM, Hamilton TC, Young RC, Klecker Jr RW and Ozols RF (1984) Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994–996.

    Google Scholar 

  • Roninson IB (1992) The role of theMDR1 (P-glycoprotein) gene in multidrug resistancein vitro andin vivo. Biochem Pharmacol 43: 95–102.

    Google Scholar 

  • Safa AR, Stern RK, Choi K, Agresti M, Tamai I, Mehta ND and Roninson IB (1990) Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gyly-185 → to Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 87: 7225–7229.

    Google Scholar 

  • Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, Van Heijningen THM, Van Kalken CK, Slovak ML, De Vries E, Van der Valk P, Meijer CJLM and Pinedo HM (1993) Overexpression of aM r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 53: 1475–1479.

    Google Scholar 

  • Schinkel AH and Borst P (1991) Multidrug resistance mediated by P-glycoproteins. Semin Cancer Biol 2: 213–226.

    Google Scholar 

  • Scotto KW, Biedler JL and Melera PW (1986) Amplification and expression of genes associated with multidrug resistance in mammalian cells. Science 232: 751–755.

    Google Scholar 

  • Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I and Gottesman MM (1986) Human multidrug resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232: 643–645.

    Google Scholar 

  • Sikic BI, Skudder SA and Evans TL (1989) Multidrug (pleiotropic) resistance in the human sarcoma cell line MES-SA. In: D Kessel (ed) Resistance to Antineoplastic Drugs (pp 37–47). CRC Press, Boca Raton, Florida.

    Google Scholar 

  • Sinha VK, Haim N, Dusre L, Kerrigan D and Pommier Y (1988) DNA strand breaks produced by etoposide (VP-16, 213) in sensitive and resistant human breast tumor cells: Implications for the mechanism of action. Cancer Res 48: 5096–5100.

    Google Scholar 

  • Sirotnak FM, Yang C-H, Mines LS, Oribe E and Biedler JL (1986) Markedly altered membrane transport and intracellular binding of vincristine in multidrug-resistant Chinese hamstor cells selected for resistance to Vinca alkaloids. J Cell Physiol 126: 266–274.

    Google Scholar 

  • Skipper HE, Schabel Jr FM and Wilcox WS (1964) Experimental evaluation of potential anticancer agents. XII, on the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep. 35: 1–111.

    Google Scholar 

  • Slapak CA, Daniel JC and Levy SB (1990) Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under Adriamycin selection: Decreased anthracycline uptake precedes increased P-glycoprotein expression. Cancer Res 50: 7895–7901.

    Google Scholar 

  • Slovak ML, Coccia M, Meltzer PS and Trent JM (1991) Molecular analysis of two human doxorubicin-resistant cell lines: Evidence for differing multidrug resistance mechanisms. Anticancer Res 11: 423–425.

    Google Scholar 

  • Slovak ML, Ho J, Bhardwag G, Kurz EU, Deeley RG and Cole SPC (1993) Localisation of novel multidrug resistance-associated gene in the HT1080/TR4 and H69AR human tumour cell lines. Cancer Res 53: 3221–3225.

    Google Scholar 

  • Slovak ML, Hoeltge GA, Dalton WS and Trent JM (1988) Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res 48: 2793–2797.

    Google Scholar 

  • Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Lowenberg B and Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255–259.

    Google Scholar 

  • Sugawara I, Iwahashi T, Okamoto K, Sugimoto Y, Ekimoto H, Tsuruo T, Ikeuchi T and Mori S (1991) Characterization of an etoposide-resistant human K562 cell line, K/eto. Jpn J Cancer Res 82: 1035–1043.

    Google Scholar 

  • Sugimoto Y, Hamada H, Tsukahara S, Noguchi K, Yamaguchi K, Sato M and Tsuruo T (1993) Molecular cloning and chatacterisation of the cDNA for theM r85,000 protein overexpressed in Adriamycin-resistant human tumor cells. Cancer Res 53: 2538–2543.

    Google Scholar 

  • Sugimoto Y, Roninson IB and Tsuruo T (1987) Decreased expression of the amplifiedmdr1 gene in revertants of multidrug-resistant human myelogenous leukemia K562 occurs without loss of amplified DNA. Mol Cell Biol 7: 4549–4552.

    Google Scholar 

  • Taylor CW, Dalton WS, Parrish PR, Gleason MC, Bellamy WT, Thompson FH, Rowe DJ and Trent JM (1991) Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell lines. Br J Cancer 63: 923–929.

    Google Scholar 

  • Toth K, Voughan MM, Slocum HK, Arredondo MA, Takita H, Baker RM and Rustum YM (1993) New immunoperoxidase “sandwich” staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formal and fixed, paraffin embedded tissues. Proc Am Assoc Cancer Res 34: 312.

    Google Scholar 

  • Tsuruo T, Iida H, Ohkochi E, Tsukagoshi S and Sakurai Y (1983) Establishment and properties of vincristine-resistant human myelogenous leukemia K562. Gann 74: 751–758.

    Google Scholar 

  • Tsuruo T, Iida-Saito H, Kawabata H, Oh-Hara T, Hamada H and Utakoji T (1986) Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant to Adriamycin and in isolated clones. Jpn J Cancer Res 77: 682–692.

    Google Scholar 

  • Twentyman PR, Fox NE, Bright KA and Bleehen NM (1986) Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cell lines. Br J Cancer 53: 529–537.

    Google Scholar 

  • Van der Bliek AM, Baas F, Houte de Lange TT, Kooiman PM, Van der Velde-Koerts T and Borst P (1987) The humanmdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively spliced mRNAs in liver. EMBO J 6: 3325–3331.

    Google Scholar 

  • Van der Bliek AM, Baas F, Van der Velde-Koerts T, Biedler JL, Meyers MB, Ozols RF, Hamilton TC, Joenje H and Borst P (1988) Genes amplified and overexpressed in human multidrug-resistant cell lines. Cancer Res 48: 5927–5932.

    Google Scholar 

  • Versantvoort CHM, Broxterman HJ, Pinedo HM, De Vries EGE, Feller N, Kuiper CM and Lankelma J (1992) Energy dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res 52: 17–23.

    Google Scholar 

  • Volm M, Bak Jr M, Efferth T and Mattern J (1989) Induced multidrug resistance in murine leukemia L1210 and associated changes in a surface membrane glycoprotein. J Cancer Res Clin Oncol 115: 17–24.

    Google Scholar 

  • Volm M, Mattern J and Pommerenke EW (1991) Timecourse of MDR gene amplification duringin vivo selection for doxorubicin-resistance and during reversal in murine leukaemia L1210. Anticancer Res 11: 579–586.

    Google Scholar 

  • Whelan RDH and Hill BT (1993) Differential expression of steroid receptors, HSP27 and pS2 in a series of drug resistant breast tumor cell lines derived following exposure to antitumour drugs or to fractionated X-irradiation. Breast Cancer Res Treat 26: 23–39.

    Google Scholar 

  • Whelan RDH, Waring CJ, Wolf CR, Hayes JD, Hosking LK and Hill BT (1992) Over-expression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistancein vitro. Int J Cancer 52: 241–246.

    Google Scholar 

  • Yoshimura A, Kuwazuru Y, Sumizuwa T, Ikeda S-I, Ichikawa M, Usagawa T and Akiyama S-I (1989) Biosynthesis, processing and half-life of P-glycoprotein in a human multidrug resistant KB cell. Biochim Biophys Acta 992: 307–314.

    Google Scholar 

  • Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, De Haas M, Smith AJ, Broxterman HJ, Mulder NH, De Vries EGE, Baas F and Borst P (1993) Analysis of the expression ofMRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747–1750.

    Google Scholar 

  • Zastawny RL, Benchimol S and Ling V (1992) Modulation of P-glycoprotein promoter activity by p53. Proc Am Assoc Cancer Res 33: 452.

    Google Scholar 

  • Zijlstra JG, De Vries EGE and Mulder NH (1987) Multifactorial drug resistance in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 47: 1780–1784.

    Google Scholar 

  • Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E, Mayes J, Sie KL, Meltzer PS and Trent JM (1990) A P-glycoprotein negative human fibrosarcoma cell line exhibiting resistance to topoisomease II-reactive drugs despite the presence of a drug-sensitive toposiomerase II. J Natl Cancer Inst 82: 1553–1561.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Cellular Chemotherapy, Imperial Cancer Research Fund, 44 Lincoln's Inn Fields, P.O. Box 123, WC2A 3PX, London, UK

    Bridget T. Hill

Authors
  1. Bridget T. Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hill, B.T. Differing patterns of cross-resistance resulting from exposures to specific antitumour drugs or to radiationin vitro . Cytotechnology 12, 265–288 (1993). https://doi.org/10.1007/BF00744668

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00744668

Key words

Search

Navigation